Discover why psoriasis treatments may lose effectiveness and explore alternatives. Learn about the potential of biologics, systemic therapies, and more to manage symptoms.

Ustekinumab showed longer drug survival than adalimumab and secukinumab in biologic-naive psoriasis patients in Denmark. Bimekizumab, guselkumab, and risankizumab had lower discontinuation risks in ...

Whether you suffer from psoriasis yourself or have heard about it from a famous Kardashian who has been very transparent about her symptoms, you know that the skin condition is far from glamorous and ...

Patients with psoriasis are at increased risk for cataracts, uveitis, dry eye disease, glaucoma, retinal vein occlusion (RVO) ...

Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

Real-world Danish registry data show that biologic drug survival in psoriasis differs between biologic-naive and ...

For the 7.5 million Americans diagnosed with psoriasis, it can be disheartening to hear that there's no cure. But there are several treatments that can help keep this autoimmune disease under control.

German registry data suggest apremilast monotherapy improves psoriasis severity and quality of life over 12 months, with ...

If you’ve struggled with itchy, irritated skin, you’ve probably sought out various creams, lotions or ointments to treat it. But if you feel like you’ve tried everything and still suffer from dry and ...

CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased ...

Psoriasis can increase skin infection risk due to effects from the condition and its treatments. Learn about potential infections, symptoms, and preventive measures.